| Juan Putra, MD | |
|
300 Longwood Ave, Boston, MA 02115-5724 | |
| (617) 355-6000 | |
| Not Available |
| Full Name | Juan Putra |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 15 Years |
| Location | 300 Longwood Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033473152 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0213X | Pathology - Pediatric Pathology | 290559 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boston Children's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Children's Hospital Pathology Foundation Inc | 0143292730 | 9 |
News Archive
EKF, has introduced the DiaSpect TM POC hemoglobin analyzer at Medica.
Patients in inpatient rehabilitation after a stroke, brain injury, or spinal cord injury have significant rates of interruptions of their rehab program—often including being transferred back to the hospital for treatment of complications, reports a study in the American Journal of Physical Medicine & Rehabilitation, the official journal of the Association of Academic Physiatrists. The journal is published by Wolters Kluwer.
Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method.
› Verified 3 days ago
| Entity Name | Children's Hospital Pathology Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376502112 PECOS PAC ID: 0143292730 Enrollment ID: O20040812001102 |
News Archive
EKF, has introduced the DiaSpect TM POC hemoglobin analyzer at Medica.
Patients in inpatient rehabilitation after a stroke, brain injury, or spinal cord injury have significant rates of interruptions of their rehab program—often including being transferred back to the hospital for treatment of complications, reports a study in the American Journal of Physical Medicine & Rehabilitation, the official journal of the Association of Academic Physiatrists. The journal is published by Wolters Kluwer.
Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Juan Putra, MD 300 Longwood Ave, Boston, MA 02115-5724 Ph: (617) 355-6000 | Juan Putra, MD 300 Longwood Ave, Boston, MA 02115-5724 Ph: (617) 355-6000 |
News Archive
EKF, has introduced the DiaSpect TM POC hemoglobin analyzer at Medica.
Patients in inpatient rehabilitation after a stroke, brain injury, or spinal cord injury have significant rates of interruptions of their rehab program—often including being transferred back to the hospital for treatment of complications, reports a study in the American Journal of Physical Medicine & Rehabilitation, the official journal of the Association of Academic Physiatrists. The journal is published by Wolters Kluwer.
Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method.
› Verified 3 days ago
Arthur J Sytkowski, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: Beth Israel Deaconess, One Deaconess Road, Boston, MA 02215 Phone: 617-632-9980 | |
Stuti Girish Shroff, MD, MBBS Pathology Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-726-2971 Fax: 617-726-7533 | |
Dr. David Kolin, M.D., PH.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St., Department Of Pathology, Boston, MA 02115 Phone: 617-732-6913 Fax: 617-277-9015 | |
Dr. Nancy Lee Harris, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Wrn 2 Pathology Associates, Boston, MA 02114 Phone: 617-726-5155 Fax: 617-726-9353 | |
Dr. Michael Gerald Drage, MD, PHD Pathology Medicare: Medicare Enrolled Practice Location: 55 Fruit St Bldg 225, Boston, MA 02114 Phone: 617-643-0800 Fax: 617-726-7474 | |
Dr. Ruth K Foreman, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Department Of Pathology, Brigham And Women's Hospital, Boston, MA 02115 Phone: 617-732-8613 | |
Celia Cobb, Pathology Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 713-469-1411 |